GSK-115648

Study Sponsor: GSK

Study Title

Consistency study of GSK Biologicals’ measles-mumps-rubella (MMR) vaccine (209762) (Priorix) comparing immunogenicity and safety to Merck & Co., Inc.’s MMR vaccine (M-M-R II), in healthy children 12 to 15 months of age

Medicine or Vaccine (generic name)

SB209762

Sponsor Identification Number

115648

Trial Registry Identification Number(#'s)

NCT01702428 2011-004891-12

Medical Condition

Measles, Mumps, Rubella

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=115648

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT01702428

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=/2011-004891-12

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

April 2019